PL441789A1 - Lipooligomoczniki, kompozycja farmaceutyczna, oraz lipooligomoczniki do zastosowania jako lek - Google Patents

Lipooligomoczniki, kompozycja farmaceutyczna, oraz lipooligomoczniki do zastosowania jako lek

Info

Publication number
PL441789A1
PL441789A1 PL441789A PL44178922A PL441789A1 PL 441789 A1 PL441789 A1 PL 441789A1 PL 441789 A PL441789 A PL 441789A PL 44178922 A PL44178922 A PL 44178922A PL 441789 A1 PL441789 A1 PL 441789A1
Authority
PL
Poland
Prior art keywords
sup
pharmaceutical composition
dab
leu
lys
Prior art date
Application number
PL441789A
Other languages
English (en)
Other versions
PL249237B1 (pl
Inventor
Sławomir Sęk
Karolina Pułka-Ziach
Joanna Juhaniewicz-Dębińska
Dariusz BARTOSIK
Robert LASEK
Damian DZIUBAK
Paulina BACHURSKA-SZPALA
Kinga BURDACH
Original Assignee
Uniwersytet Warszawski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski filed Critical Uniwersytet Warszawski
Priority to PL441789A priority Critical patent/PL249237B1/pl
Priority to CA3261961A priority patent/CA3261961C/en
Priority to PCT/IB2023/057366 priority patent/WO2024018398A1/en
Priority to JP2025502831A priority patent/JP2025525741A/ja
Priority to EP23765305.0A priority patent/EP4558512B1/en
Priority to ES23765305T priority patent/ES3070603T3/es
Priority to CN202380054481.1A priority patent/CN119604520A/zh
Priority to KR1020257004771A priority patent/KR20250037534A/ko
Priority to PL23765305.0T priority patent/PL4558512T3/pl
Publication of PL441789A1 publication Critical patent/PL441789A1/pl
Publication of PL249237B1 publication Critical patent/PL249237B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G71/00—Macromolecular compounds obtained by reactions forming a ureide or urethane link, otherwise, than from isocyanate radicals in the main chain of the macromolecule
    • C08G71/02—Polyureas
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L75/00—Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
    • C08L75/02—Polyureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Przedmiotem zgłoszenia jest lipooligomocznik o wzorze (1) FA-Phe<sup>u</sup> -Xaa1<sup>u</sup> - Xaa2<sup>u</sup> - Leu<sup>u</sup> - Xaa3<sup>u</sup> - NH<sub>2</sub>, w którym FA oznacza liniową lub rozgałęzioną resztę kwasu karboksylowego zawierającego od 6 do 15 atomów węgla w łańcuchu alkilowym; Xaa1<sup>u</sup> oznacza Lys<sup>u</sup> albo Dab<sup>u</sup> albo Arg<sup>u</sup>; Xaa2<sup>u</sup> oznacza Lys<sup>u</sup> albo Dab<sup>u</sup> albo Leu<sup>u</sup> albo Arg<sup>u</sup>; Xaa3<sup>u</sup> oznacza Lys<sup>u</sup> albo Dab<sup>u</sup> albo Leu<sup>u</sup> albo Arg<sup>u</sup>. Zgłoszenie dotyczy także kompozycji farmaceutycznej zawierającej lipooligomocznik o wzorze (1).
PL441789A 2022-07-19 2022-07-19 Lipooligomocznik, lipooligomocznik do zastosowania jako lek oraz kompozycja farmaceutyczna PL249237B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL441789A PL249237B1 (pl) 2022-07-19 2022-07-19 Lipooligomocznik, lipooligomocznik do zastosowania jako lek oraz kompozycja farmaceutyczna
CA3261961A CA3261961C (en) 2022-07-19 2023-07-19 Lipooligoureas, pharmaceutical composition, and lipooligoureas for use as medicament
PCT/IB2023/057366 WO2024018398A1 (en) 2022-07-19 2023-07-19 Lipooligoureas, pharmaceutical composition, and lipooligoureas for use as medicament
JP2025502831A JP2025525741A (ja) 2022-07-19 2023-07-19 リポオリゴ尿素、医薬組成物、及び薬剤としての使用のためのリポオリゴ尿素
EP23765305.0A EP4558512B1 (en) 2022-07-19 2023-07-19 Lipooligoureas, pharmaceutical composition, and lipooligoureas for use as medicament
ES23765305T ES3070603T3 (en) 2022-07-19 2023-07-19 Lipooligoureas, pharmaceutical composition, and lipooligoureas for use as medicament
CN202380054481.1A CN119604520A (zh) 2022-07-19 2023-07-19 脂低聚脲、药物组合物和用作药物的脂低聚脲
KR1020257004771A KR20250037534A (ko) 2022-07-19 2023-07-19 리포올리고우레아, 약학 조성물, 및 의약으로서 사용하기 위한 리포올리고우레아
PL23765305.0T PL4558512T3 (pl) 2022-07-19 2023-07-19 Lipooligomoczniki, kompozycja farmaceutyczna, oraz lipooligomoczniki do zastosowania jako lek

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441789A PL249237B1 (pl) 2022-07-19 2022-07-19 Lipooligomocznik, lipooligomocznik do zastosowania jako lek oraz kompozycja farmaceutyczna

Publications (2)

Publication Number Publication Date
PL441789A1 true PL441789A1 (pl) 2024-01-22
PL249237B1 PL249237B1 (pl) 2026-03-16

Family

ID=89617283

Family Applications (2)

Application Number Title Priority Date Filing Date
PL441789A PL249237B1 (pl) 2022-07-19 2022-07-19 Lipooligomocznik, lipooligomocznik do zastosowania jako lek oraz kompozycja farmaceutyczna
PL23765305.0T PL4558512T3 (pl) 2022-07-19 2023-07-19 Lipooligomoczniki, kompozycja farmaceutyczna, oraz lipooligomoczniki do zastosowania jako lek

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL23765305.0T PL4558512T3 (pl) 2022-07-19 2023-07-19 Lipooligomoczniki, kompozycja farmaceutyczna, oraz lipooligomoczniki do zastosowania jako lek

Country Status (7)

Country Link
EP (1) EP4558512B1 (pl)
JP (1) JP2025525741A (pl)
KR (1) KR20250037534A (pl)
CN (1) CN119604520A (pl)
ES (1) ES3070603T3 (pl)
PL (2) PL249237B1 (pl)
WO (1) WO2024018398A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL249237B1 (pl) * 2022-07-19 2026-03-16 Univ Warszawski Lipooligomocznik, lipooligomocznik do zastosowania jako lek oraz kompozycja farmaceutyczna

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548883A2 (en) * 2010-03-10 2013-01-23 Universidad de Barcelona Peptide compounds that can be used as antibacterial agents
WO2018109042A2 (en) * 2016-12-13 2018-06-21 Ferring B.V. Antimicrobial peptides
PL431336A1 (pl) * 2019-10-01 2021-04-06 Uniwersytet Warszawski Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL249237B1 (pl) * 2022-07-19 2026-03-16 Univ Warszawski Lipooligomocznik, lipooligomocznik do zastosowania jako lek oraz kompozycja farmaceutyczna

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548883A2 (en) * 2010-03-10 2013-01-23 Universidad de Barcelona Peptide compounds that can be used as antibacterial agents
WO2018109042A2 (en) * 2016-12-13 2018-06-21 Ferring B.V. Antimicrobial peptides
PL431336A1 (pl) * 2019-10-01 2021-04-06 Uniwersytet Warszawski Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TALLET, L.; FRISCH, E.; BORNERIE, M.; MEDEMBLIK, C.; FRISCH, B.; LAVALLE, P.; GUICHARD, G.; DOUAT, C.; KICHLER A.: "Molecules 2022, 27, 1749", DESIGN OF OLIGOUREA-BASED FOLDAMERS WITH ANTIBACTERIAL AND ANTIFUNGAL ACTIVITIES. *

Also Published As

Publication number Publication date
KR20250037534A (ko) 2025-03-17
EP4558512B1 (en) 2026-02-11
JP2025525741A (ja) 2025-08-07
WO2024018398A1 (en) 2024-01-25
PL249237B1 (pl) 2026-03-16
PL4558512T3 (pl) 2026-07-27
ES3070603T3 (en) 2026-06-16
EP4558512A1 (en) 2025-05-28
CA3261961A1 (en) 2024-01-25
EP4558512C0 (en) 2026-02-11
CN119604520A (zh) 2025-03-11

Similar Documents

Publication Publication Date Title
RU2012108874A (ru) Композиции, содержащие расщепляемые ферментами опиоидные пролекарства с модифицированным кетоном и их дополнительные ингибиторы
PE20090211A1 (es) Inhibidores de las iap
CY1112353T1 (el) Παραγωγα μεταστινης και χρηση αυτων
BRPI0620027A2 (pt) inibidores da protease soft e formas pró-soft
PE20081838A1 (es) Derivados de ester o amida de imidazolilo como moduladores del receptor glucocorticoide
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
WO2008096845A1 (ja) 油剤ならびにそれを含有する潤滑剤、保湿剤および外用剤
UA95913C2 (ru) Соединение, пригодное как присадка к топливу, способ ее получения, композиция присадки и топливо
PE20130222A1 (es) Activadores de guanilato ciclasa soluble
AR039672A1 (es) Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat)
BRPI0418368A (pt) derivados de (3-oxo-3,4-dihidro-quinoxalin2-ilamino)-benzamida e compostos afins, como inibidores de glicogênio fosforilase para o tratamento de diabetes e obesidade
BR112022003169A2 (pt) Formulações de anticorpo anti-il-23p19
MX9707531A (es) Nuevos compuestos heterociclicos.
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
BRPI0418474A (pt) solução aquosa parenteral estável
MY145663A (en) Heterocyclic compounds containing nitrogen as a fuel additive in order to reduce abrasion
PE20090362A1 (es) Derivados de piperidina/piperazina como moduladores de dgat
EP4321523A3 (en) Hemiasterlin derivatives and antibody-drug conjugates including same
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
CY1118131T1 (el) Φαρμακο δραστικο στο νευροπαθητικο αλγος
IL174410A0 (en) Large scale preparation of alpha-1 proteinase inhibitor and use thereof
BRPI0609783A8 (pt) composto, utilização do mesmo, composição farmacêutica ou cosmética, e, utilização cosmética de um composto
PE20110663A1 (es) Pirrolidinas
MX2025006952A (es) Inhibidores y/o degradadores que contienen 3-fluoro-4-hidroxibenzmida y usos de estos
MX2024005267A (es) Moduladores de akt3.